bill van <
bil...@delete.shaw.ca> wrote in
news:billvan-ED70D4...@shawnews.vc.shawcable.net: 
I'm sympathetic to that point of view.  On a somewhat related note, the NY 
Times had an interesting article yesterday about a key regulator of cancer 
treatments and issues about the pace of approvals.
http://nyti.ms/1Jl8Xh0
It's obviously very easy for treatments to get bogged down in the approval 
process.
I think this is a good couple of pieces by Michael Specter from 
newyorker.com on some of the issues --
http://tinyurl.com/pk3d6ou
http://tinyurl.com/p9anb4j
I'm not saying the research should be banned, but we really don't have a 
good regulatory framework in place for handling it.  And just as it's easy 
to demogogue against genetic research, it's also extremely to do the same 
thing for it.  
The first article describes one possible approach to eliminating Lyme 
Disease by rewriting the genes of wild mice to eliminate their ability to 
act as hosts.  It includes a telling sentence:
   Esvelt [the researcher] stressed that such an approach would 
   become possible only after much more research and a 
   lengthy series of public discussions on the risks and benefits 
   of the process.
The first part of that sentence is true -- much more work is needed.  But 
the second is not -- there is little forcing public discussions on risks 
and benefits, and it would be fairly trivial for agribusiness lobbyists to 
gain extremely relaxed standards if a Republican was elected president, and 
it could also happen under a Democrat, though somewhat less likely.
That need for public discussion is the point of the second Michael Specter 
piece.  Monsanto did early GMO work largely in secret and acted with a 
great lack of transparency, and to this day sees the issue through the lens 
of PR and trade secrecy rather than science.  That lack of open discussion 
is a major reason for the backlash, but I see little sign that future 
agricultural or medical business interests will act very differently.
We also don't have a good legal framework for handling related IP issues, 
and I think it's worth wondering what happens if key developments get 
walled off by patent owners -- we may well end up with a sympathetic 
government structure enforcing private regulation of cancer treatments, for 
example.  As the Martin Shkreli case shows, it's pretty easy for companies 
to game the current system to control the supply of essential drugs, and in 
the US the courts, patent system and Congress have been extremely bad at 
figuring out current IP issues, which isn't encouraging for what they'll do 
with CRISPR-related research.